What other conditions besides primary osteoporosis could cause bone fragility in a post‑menopausal woman with a fragility fracture?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Secondary Causes of Bone Fragility in Postmenopausal Women

In a postmenopausal woman with a fragility fracture, you must systematically evaluate for secondary causes of osteoporosis, which are present in 50-67% of such patients and fundamentally alter treatment approach. 1, 2

Why This Matters

Secondary causes are found in approximately 50% of postmenopausal women with osteoporosis and 67% of those with low bone mineral density who present with fragility fractures 1. Critically, these secondary factors occur equally across all BMD categories—including those with normal BMD, osteopenia, and osteoporosis 2. This means you cannot rely on BMD alone to determine who needs evaluation.

Specific Conditions to Evaluate

Endocrine Disorders

  • Hypercortisolism (including mild autonomous cortisol secretion—MACS—which causes fractures even at near-normal cortisol levels) 3
  • Primary hyperparathyroidism (preferentially decreases cortical bone at hip and radius) 4
  • Secondary hyperparathyroidism (found in 6% of fracture patients) 2
  • Hyperthyroidism (untreated, long-standing) 5
  • Hypogonadism or premature menopause 5
  • Primary aldosteronism (promotes fragility via mineralocorticoid receptor activation, oxidative stress, and hypercalciuria) 3

Metabolic and Nutritional Disorders

  • Vitamin D deficiency (when severe, causes osteomalacia with bone pain and muscle weakness, not just asymptomatic osteoporosis) 6
  • Hypercalciuria (PTH-dependent vs. PTH-independent—differentiation is crucial for management) 3
  • FGF23-dependent phosphate-wasting disorders (impair mineralization) 3
  • Chronic malnutrition or malabsorption 5
  • Chronic liver disease 5

Hematologic Conditions

  • Monoclonal gammopathy (found in 13% of fracture patients) 2

Renal Disease

  • Chronic kidney disease (present in 13% of fracture patients) 2

Rheumatologic Conditions

  • Rheumatoid arthritis (accounts for 3% of cases, included in FRAX) 4, 2
  • Ankylosing spondylitis 7
  • Systemic lupus erythematosus 7
  • Other erosive inflammatory arthritides 7

Medication-Induced Bone Loss

  • Glucocorticoids (≥5 mg prednisone daily for ≥3 months—found in 12% of fracture patients) 8, 2
  • Anti-androgenic therapy for prostate cancer 7
  • Aromatase inhibitor therapy for breast cancer 7

Lifestyle and Behavioral Factors

  • Chronic alcoholism (>3 drinks daily—found in 12% of fracture patients) 5, 2
  • Current smoking (18% of fracture patients) 2
  • Type 1 diabetes 5
  • Osteogenesis imperfecta in adults 5

Structured Laboratory Evaluation

For any postmenopausal woman with a fragility fracture, obtain these specific tests (92% sensitivity for detecting secondary causes) 6:

Essential Laboratory Panel

  • 25-hydroxyvitamin D (not 1,25-dihydroxyvitamin D)
  • Parathyroid hormone (PTH)
  • Serum calcium and phosphate
  • 24-hour urine calcium
  • Serum creatinine (assess renal function)
  • Complete blood count (screen for hematologic disorders)
  • Liver function tests
  • Thyroid-stimulating hormone
  • Serum protein electrophoresis (given 13% prevalence of monoclonal gammopathy) 2

Additional Tests Based on Clinical Suspicion

  • Testosterone in men with hypogonadism
  • 24-hour urinary free cortisol or overnight dexamethasone suppression test if Cushing's suspected
  • Tissue transglutaminase antibodies if malabsorption suspected

Critical Clinical Pitfalls

  1. Don't assume normal BMD excludes secondary causes: 17% of patients with normal BMD have secondary factors contributing to their fracture 2

  2. Don't skip evaluation in "typical" osteoporosis: Even postmenopausal women who appear to have primary osteoporosis have a 50% chance of having a treatable secondary cause 1

  3. Recognize vitamin D deficiency vs. osteomalacia: Severe vitamin D deficiency presents with bone pain, muscle weakness, low calcium/phosphorus, elevated alkaline phosphatase and PTH—not just low BMD 6

  4. HIV infection is a risk factor: All HIV-infected postmenopausal women should be screened, as HIV itself is associated with low BMD independent of other factors 6

When to Suspect Secondary Osteoporosis

Evaluate for secondary causes in these specific scenarios 5:

  • Any fragility fracture regardless of BMD
  • Z-score ≤ -2.0 (suggests secondary cause rather than age-related bone loss) 4
  • Premenopausal women with low BMD or fracture
  • Men of any age with low BMD or fracture
  • Postmenopausal women <65 years with fracture
  • Rapid bone loss on serial DXA (>3-5% annually at spine or hip)
  • Fracture despite adequate osteoporosis treatment

Why This Changes Management

Identifying secondary causes is not academic—many are reversible or require specific treatment beyond standard osteoporosis therapy 7, 9. For example:

  • Correcting vitamin D deficiency prevents osteomalacia
  • Treating hyperparathyroidism may reverse bone loss
  • Discontinuing causative medications when possible
  • Addressing hypercortisolism improves bone quality
  • Treating malabsorption restores calcium absorption

The presence of secondary osteoporosis increases fracture risk 2-3 fold beyond what BMD alone would predict 6, making identification and treatment essential for effective fracture prevention.

References

Research

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology, 2026

Guideline

acr appropriateness criteria® osteoporosis and bone mineral density: 2022 update.

Journal of the American College of Radiology, 2022

Guideline

american association of clinical endocrinologists/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2020

Research

The management of secondary osteoporosis.

Best practice & research. Clinical rheumatology, 2005

Guideline

acr appropriateness criteria<sup>®</sup> osteoporosis and bone mineral density.

Journal of the American College of Radiology, 2017

Research

Secondary osteoporosis in patients with an osteoporotic fracture.

Best practice & research. Clinical rheumatology, 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.